Studies of immediate adverse reactions to different doses of a slow-release preparation of isoniazid

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Safety

Background:

• Isoniazid is a key anti-tuberculosis drug.
• Slow-release formulations aim to improve drug delivery and patient compliance.
• Assessing adverse reactions of new drug formulations is crucial for patient safety.

Purpose of the Study:

• To evaluate immediate adverse reactions to varying doses of matrix isoniazid.
• To determine the safety profile of matrix isoniazid in a specific patient population.

Main Methods:

• Conducted double-blind studies to assess adverse events.
• Administered different doses of matrix isoniazid.
• Monitored patients for immediate and delayed adverse reactions, including giddiness and gastro-intestinal symptoms.

Main Results:

• Matrix isoniazid at 30 mg/kg was well-tolerated.
• Higher doses of matrix isoniazid led to a dose-related incidence of giddiness.
• Giddiness had a late onset and often persisted for 24 hours.
• Some patients reported gastro-intestinal issues.

Conclusions:

• Matrix isoniazid can be safely administered to Madras patients at doses of 30-40 mg/kg.
• The incidence of immediate adverse reactions is acceptable within this dosage range.